Revolution Medicines (RVMD) Intangibles (2019 - 2026)

Revolution Medicines has reported Intangibles for 8 years, with the latest figure at $63.3 million in Q2 2026.

• On a quarterly basis, Intangibles changed 0.0% year-over-year to $63.3 million in Q2 2026; TTM through Jun 2026 was $63.3 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $63.3 million, changed 0.0% from the prior year.
• Intangibles was $63.3 million for Q2 2026 at Revolution Medicines, roughly flat from $63.3 million in the prior quarter.
• The five-year high for Intangibles was $63.3 million in Q1 2022, with the low at $58.5 million in Q1 2023.
• Average Intangibles over 5 years is $63.0 million, with a median of $63.3 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Intangibles slipped 7.49% in 2023, then grew 8.1% in 2024.
• Over 5 years, Intangibles stood at $63.3 million in 2022, then changed by 0.0% to $63.3 million in 2023, then changed by 0.0% to $63.3 million in 2024, then changed by 0.0% to $63.3 million in 2025, then changed by 0.0% to $63.3 million in 2026.
• The last three Intangibles figures came in at $63.3 million (Q2 2026), $63.3 million (Q1 2026), and $63.3 million (Q4 2025), per Business Quant data.